Wednesday, 9 Apr 2008 | Source: Reuters
Pfizer Inc. and Nektar Therapeutics said on Wednesday clinical trials of the inhaled insulin Exubera found increased cases of lung cancer, leading Nektar to end talks with potential partners to market the product.
Wednesday, 9 Apr 2008 | Source: Reuters
Pfizer and Nektar Therapeutics said Wednesday clinical trials of the inhaled insulin Exubera found increased cases of lung cancer, leading Nektar to end talks with potential partners to market the product.
Posts |
COMPANY : MannKind Corp
10 Apr 2008
This morning there's a plethora of stuff to blog about: the Takeda-Millennium deal, more commentary about Merck and Schering-Plough and the extent of the Vytorin/Zetia fallout, Genentech's biotech bellweather earnings after the closing bell today, just to name a few... Read More
7 Mar 2008
First, Pfizer gave up on its inhaled insulin Exubera, then NovoNordisk threw in the towel and now it looks like Lilly is going to bow out... Read More
VIDEO | COMPANIES : MannKind Corp
Insight on how the Gulf Coast refineries have fared in the aftermath of Gustav, with Bill Day, Valero VP, corp communica...
An inside perspective on the Democratic Convention, with Don Peebles, Peebles Corp. CEO
Debating whether the Fed is listening too closely to what Wall Street wants, with Brian Wesbury, of First Trust Advisors...
More Videos
HOME | NEWS | MARKETS | EARNINGS | INVESTING | VIDEO | CNBC TV | CNBC PLUS | CNBC HD+
About CNBC | Site Map | Privacy Policy | Terms of Service | Advertise | Help | Feedback | Video Reprints
About CNBC | Site Map | Privacy Policy | Terms of Service | Advertise | Help | Feedback | Video Reprints
Partners: AOL Money | BloggingStocks.com
(c) 2008 CNBC, Inc. All Rights Reserved
Data is a real-time snapshot *Data is delayed at least 15 minutes